tiprankstipranks
Advertisement
Advertisement

OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option

Story Highlights
  • OKYO Pharma expanded its February 2026 U.S. equity offering as Piper Sandler bought an additional 1.1 million shares on March 12.
  • The partial option exercise increased total gross proceeds to about $22 million, bolstering OKYO Pharma’s funding and balance sheet flexibility.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option

Claim 55% Off TipRanks

OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an update.

OKYO Pharma Ltd has expanded a previously announced U.S. underwritten equity offering that originally closed on February 17, 2026, in which it sold 10,815,000 ordinary shares at $1.85 per share. On March 12, 2026, underwriter Piper Sandler & Co. partially exercised its 30-day option and purchased an additional 1,109,060 ordinary shares from the company.

The partial option exercise lifts the total gross proceeds from the offering to approximately $22 million before fees and expenses, with all shares being primary issuance by OKYO Pharma. The capital raise, conducted under the company’s effective Form F-3 shelf registration, provides additional funding flexibility and may strengthen the firm’s balance sheet and support its ongoing operational and strategic initiatives.

The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.

The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Ltd is a foreign private issuer listed in the United States and headquartered in London, operating in the pharmaceutical and life sciences sector. The company issues ordinary shares to U.S. investors via underwritten public offerings and utilizes SEC-registered shelf offerings to access the capital markets for its funding needs.

Average Trading Volume: 268,001

Technical Sentiment Signal: Sell

Current Market Cap: $87.84M

See more data about OKYO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1